Study
Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly: Immune, Cognitive, and Functional Consequences (Phase 2)
Phase 2 substudy in 20 older adults measures cardiac MRI effects of mTOR inhibition, University of Texas Health Science Center at San Antonio. Active, not recruiting. Primary completion October 2026.
NCT04742777 is a Phase 2 substudy from the University of Texas Health Science Center at San Antonio testing mTOR inhibition and other metabolism-modulating interventions in older adults, with immune, cognitive and functional endpoints. This substudy uses cardiac MRI with late gadolinium enhancement in 20 participants. Started February 2022. Active, not recruiting, primary completion 16 October 2026.
This work sits in the same research program as the PEARL and other rapamycin aging trials at UT Health San Antonio, where Matt Kaeberlein's PEARL trial separately tested rapamycin dosing in healthy adults.
The substudy is small and imaging-focused. It cannot move rapamycin's evidence grade for longevity outcomes on its own. Rapamycin stays at evidence grade B: strong mouse lifespan data and growing but small human trials.
No results posted yet. Registry status: active, not recruiting; primary completion 16 October 2026.
N=20 imaging substudy; check whether rapamycin or another mTOR inhibitor is the intervention arm before citing. Results due soon after October 2026.
registered-trial-no-results
Active substudy with no published results. Registry record only, tier 4.
- R
- e
- s
- u
- l
- t
- s
- a
- f
- t
- e
- r
- t
- h
- e
- O
- c
- t
- o
- b
- e
- r
- 2
- 0
- 2
- 6
- p
- r
- i
- m
- a
- r
- y
- c
- o
- m
- p
- l
- e
- t
- i
- o
- n
- d
- a
- t
- e
- .
Expected readout: Cardiac MRI findings from the mTOR inhibition arm, expected late 2026 or 2027. · Decision recorded 2026-09-28
Cited by
1 encyclopedia entries reference this study.